Trichostatin A (TSA)

For research use only.

Catalog No.S1045

160 publications

Trichostatin A (TSA) Chemical Structure

CAS No. 58880-19-6

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
USD 247 In stock
USD 617 In stock
USD 1237 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Trichostatin A (TSA) has been cited by 160 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 Mmi1SpVv[3Srb36gRZN{[Xl? MYGwMlfPxE1? NIPnfnUzPGh? MXvleIhidm:u NX;hflZ[\W6qYX7j[ZMhTU6jQzDhZ4V1gWyjdHnvckBidmRiaX7jdoVie2W|IFXOZWMh[WK3bnThcoNmKGmwIITo[UB1d3SjbDDj[YxtKGy7c3H0[UBidmRiYYSgeIhmKGOnbHygd5Vz\mGlZR?= MoHmNlU4QDdyN{m=
TE13 NFnKPGlHfW6ldHnvckBCe3OjeR?= NX3QOYpZOC5|zszN NXnURpplOjSq MXr1dE1z\We3bHH0[ZMhWkGVU1[1RUBt\X[nbB?= MUOyOVU4QTZ4NR?=
TE13 MV;BdI9xfG:|aYOgRZN{[Xl? NIr6UpYxNjQQvF2= M3S5eFI1cA>? NEPMO|JqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w NGC2eIozPTV5OU[2OS=>
MEFs NXn0NI17TnWwY4Tpc44hSXO|YYm= NY\rVHRmPc7:TR?= MUGxOog> NIPNUGpqdmO{ZXHz[ZMhfGinIFXQSWMh[XS2YXPocYVvfCxiVHnyJIRmdGm4ZYL5JIFv\CC2aHWg[YZncWOrZX7jfUBw\iCyZXTld5RidCCob4LtZZRqd25? NWLDTHBFOjV2OEK2N|Q>
SW480  NXe0NXk6TnWwY4Tpc44hSXO|YYm= MoPYNE4y|ryP NVSwPJY2PDiq NUjZPVlwTE2VTx?= MonsdoV3\XK|ZYOgSW1V NXnTWpFwOjV2M{S5PVc>
PC3  M37OeGZ2dmO2aX;uJGF{e2G7 MVqwMlHPxE1? M4HD[VQ5cA>? NXzPeGc3TE2VTx?= Ml7SdoV3\XK|ZYOgSW1V M3rYWlI2PDN2OUm3
SW480  NGPCOZZHfW6ldHnvckBCe3OjeR?= NWHHPXdJOC5zzszN MXe0PIg> Ml7JSG1UVw>? MmC2ZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w MnXkNlU1OzR7OUe=
PC3  MnL1SpVv[3Srb36gRZN{[Xl? MWiwMlHPxE1? M2G0TVQ5cA>? MV7EUXNQ MmXRZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w MUKyOVQ{PDl7Nx?=
SW480  MnXsSpVv[3Srb36gRZN{[Xl? NWXhfnl6OC5zzszN MUC0PIg> NE\SPIpFVVOR MVvpcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz M2Px[VI2PDN2OUm3
PC3  MXvGeY5kfGmxbjDBd5NigQ>? M{XPd|AvOc7:TR?= MnrFOFhp NFzoOJZFVVOR NI[1[ItqdmS3Y3XzJIlv[3KnYYPlJI9nKEiGQVOxJIFv\CCKRFHDNkBwdiCVbIXnJIdmdmW|IIDyc41wfGW{ MXGyOVQ{PDl7Nx?=
A431 NX;FNpJ6SXCxcITvd4l{KEG|c3H5 NYrmcIc{Oi9zMD:1NE8yODCwTR?= NXi5c5NqPDiq M2rrfmROW09? M1T0VIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aB?= M1e3c|I2OzdzME[5
A431 M3zjWGZ2dmO2aX;uJGF{e2G7 M1y4e|Uxdk1? NVL4OpFDOi94L{GyM|I1cA>? M1X1e2ROW09? M4m4VoFkfGm4YYTld{BxOjFiYX7kJIlvcGmkaYTzJGFVTjNiZYjwdoV{e2mxbh?= M2fybVI2OzdzME[5
MDA-MB-231 MmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjzUFQxNTZyMH7N MkDiNlRp M{P3UmROW09? M13TO2lEPTBib3[gNVAxdk1? MknzNlUyQTJ5MkG=
MCF7 M3S1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWwMVYxOG6P MWGyOIg> MlfNSG1UVw>? M3;5[GlEPTBib3[gO|VvVQ>? M4f0NVI2OTl{N{Kx
SKOV-3 Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXtN|JUOS1zMN88US=> MWOyOIg> M4WyN2ROW09? MVzJR|UxKG:oIEWuOu69VQ>? MYWyOVE3QTR7MR?=
A549 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37JZlEuOTEQvF2= NEPvbm4zPGh? MUXEUXNQ NVTvb21ZUUN3MDDv[kA{NjMQvF2= M{LyOVI2OTZ7NEmx
SKOV-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\2W|AvOS1zzszN NWLtSmFLPDiq M4nBR2ROW09? NY\CO4tRUUN3MDDv[kAxNjgQvF2= Mm[yNlUyPjl2OUG=
A549 M2XiNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\HbVAvOS1zzszN NUOyeYdDPDiq M2TVPWROW09? NGqxc4lKSzVyIH;mJFAvOjkQvF2= Mn[1NlUyPjl2OUG=
SKOV-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLkdnNQOC5yMT2wMlnPxE1? NWPL[lJGPzKq M3fDU2ROW09? M4fXdWlEPTBib3[gNE4{Os7:TR?= NXrabo9pOjVzNkm0PVE>
A549 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M176elAvODFvMD65{txO MWG3Nog> NEfYVXVFVVOR MlrZTWM2OCCxZjCwMlA3|ryP NGTQPY0zPTF4OUS5NS=>
HeLa MXfGeY5kfGmxbjDBd5NigQ>? NUG3UYRUOjVybl2= NInadVYyPmh? M{K0XGROW09? NHTuUnRqdmO{ZXHz[ZMhS1mSMVGxJI1TVkFiZYjwdoV{e2mxbtMg NVfqOmJbOjVzMU[2PFg>
CNE2 MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEixd|EyODBvNkCwcm0> MlfUNlQwPDhxN{Lo MYDpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3mwclI1QTZ7OUCx
PC3 M3;2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX2xNFAuOTByMH7N MViyOIg> NGix[ZhKSzVyIH;mJFMxOG6P Mly2NlQ5PTR4NUi=
LNCaP NFnRXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXSNVAxNTFyMEDuUS=> M{TUelI1cA>? MnzTTWM2OCCxZjCzNFBvVQ>? NXTBR|RjOjR6NUS2OVg>
HeLa  NIi5WotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe2N4gz|ryP MlvXOFhp NHTGSmtl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZYJwfXRiMkWl NUezZWVxOjR6NE[xN|U>
HMEC-1  MljUSpVv[3Srb36gRZN{[Xl? NIj3[pk{ODCwTR?= M3rJSlI1cA>? MXnpcoNz\WG|ZYOg[ZhxemW|c3nvckBw\sLiVlXHSnI{yqCvUl7B M3q0WFI1PzFyNkOx
HeLa MkP0SpVv[3Srb36gRZN{[Xl? NYPiTllnOW2P NFrlSZgxNjWq NVPt[JRW[WKxbHnzbIV{KHSqZTD0c5RidCCKRFHDJIFkfGm4aYT5 M1niblI1PzB5NEe0
ACP02 M2P3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPIS4ozPTBxM{WwM|UxOG6P NEfWRnAzPGh? Ml;L[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? NGi1VI0zPDZ4OEW0Oy=>
ACP03 NIPMS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jVUFI2OC9|NUCvOVAxdk1? MlP4NlRp MknH[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? M{XWOlI1PjZ6NUS3
U87 GBM M3K5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy4[3MyODBxM{CwM|UxOCCwTR?= MX[3NkBp M2O5e|ExOCViZYToZY5wdA>? MkXSdoVlfWOnczDt[YFvKGOnbHygcpVu[mW{IHL5JFMyNCB3NDygZY5lKDV6wrCl MWCyOFQ3PDh2MR?=
U87 GBM MVrGeY5kfGmxbjDBd5NigQ>? M125SVExOC93MECgUo0> M{S0NlQ5KGh? M4XRe|ExOCViZYToZY5wdA>? NEnjVWFKdmS3Y3XzJHNmdmW|Y3XuZ4UuVGmtZTDBcJRmemG2aX;ud{BqdiCQdXPs[YFzKE2xcoDoc4xw\3l? MlSxNlQ1PjR6NEG=
RPE NFLKc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:wMlIwOC52L{CuPE8yKM7:TR?= NYfPfHlbOjRxNEivO|IhcA>? M2TEW2ROW09? NXf4bW03cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44h[nliY3XscEBkgWOuZTDhdpJme3R? NFPVPYozPDR3Nk[wNi=>
HT29  M1TYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\jc2hLOThyIH7N M1TjTlczKGh? MoLiTWM2OCCxZjCxPFAhdk1? NYHOU|VbOjR|NkiyOlU>
hMSCs M4\tcmZ2dmO2aX;uJGF{e2G7 M3PSd|YvOjVibl2= NH\DenIzPCCq MlzLSG1UVw>? NGrCPYV{fGGkaXzpfoV{KEirc4TvcoUhSWOndInsZZRqd25iYX7kJJRp\SCHeIDy[ZN{cW:wIH;mJHBtfXKrcH;0[Y51KEenbnXz NUPBRWM1OjR|MUKzOVY>
Huh7  MlHRSpVv[3Srb36gRZN{[Xl? NYW5U484OC5zL{CuOU8yNjBizszN M37hclI1cA>? NIf3dZV{fXCycnXzd4V{KFmWSFTDNkBo\W6nIHX4dJJme3Orb36= M{XCT|I1OjZ7Nkey
SKOV3 NFjJVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPW[Xh1OC5yNT2yJO69VQ>? NUe4SZVLOTBxMkSvOFghcA>? MnG1SG1UVw>? MWPt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NGr1cI8zPDJ{M{iwNS=>
A2780 MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e4RlAvODVvMjFOwG0> MYCxNE8zPC92ODDo NGrHOmpFVVOR MXnt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NUnldphZOjR{MkO4NFE>
SRA01/04  MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7YWI9VOC5{IN88US=> MXK0PEBp NVnmVm86TE2VTx?= Ml\Jd5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM> NGDkXokzPDF3N{i3PC=>
HLEB3 M2rrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfXNE4zKM7:TR?= MnLBOFghcA>? NYDSPIFGTE2VTx?= NF\oTlJ{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>? MYOyOFE2Pzh5OB?=
SRA01/04  M176c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLJNE41NzBwODFOwG0> NUn5ZpVVPDhiaB?= NGrXdIVFVVOR NG\leolqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NEXKZXQzPDF3N{i3PC=>
HLEB3 M3X5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVywMlQwOC56IN88US=> NHrOeXY1QCCq NIi5RnZFVVOR NYj4SHQycW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NHrxe44zPDF3N{i3PC=>
HCT116 NX7lZnpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PHflAvOiEQvF2= MYKxNkBp M3fIc4VvcGGwY3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgdoFlcWG2aX;u NFfCflIzPDF{MkKzNS=>
CA46 NIn5R2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Hmd|MwPi9zMj:yOE81QCCwTR?= NIrNbI41QCCq MlfUbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCjdDCyOEBidmRiNEigcm3DqA>? MVSyOFA3PDl3MR?=
PMNs M{SxdGZ2dmO2aX;uJGF{e2G7 MojJN|Ahdk1? MnP5OFghcA>? NEPvb3JqdmirYnn0d{Bm\m[ncn;jfZRwe2m|LDDISGFEKGGldHn2bZR6KGGwZDDSZYMh[WO2aY\peJk> MXmyN|k5QDZzNx?=
H1299 M{XNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrjR2oyyqEQvF5CpC=> MljINlQwPDhxN{KgbC=> MVzleIhidm:u NW\jVVZRcW6lcnXhd4V{KGOnbHyg[IVifGhiYX\0[ZIhOjSq MWSyN|kyPjZyOR?=
A549 M1T3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fqdFAvOjVxMD61M|Eh|ryP MmfaNlQwPDhxN{KgbC=> MWTleIhidm:u M1nqRolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NX2yWXh1OjN6Nke5PVE>
H1299 M1nseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rBflAvOjVxMD61M|Eh|ryP NFTVOo0zPC92OD:3NkBp MkDO[ZRp[W6xbB?= MV3pcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NXXIZ|Q6OjN6Nke5PVE>
A549 NIjyVlZCeG:ydH;zbZMhSXO|YYm= MmjLNE42NzFizszN NUfoNXdkPDhiaB?= M3HIfIV1cGGwb3y= MUfpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MmXxNlM5Pjd7OUG=
H1299 NFrlUZFCeG:ydH;zbZMhSXO|YYm= NWfNW5FnOC53L{Gg{txO MoPXOFghcA>? MUXleIhidm:u NFL1WGxqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M2jzc|I{QDZ5OUmx
SUM149PT NFjMVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf2Nk84NjVxMUCg{txO NH;FNIw1QCCq NF\PNWZFVVOR NWXxe25YcW6mdXPld{Bk\WyuIHTlZZRpKGG2IEKg{txOKGmwc3Xud4l1cX[nbIm= M{P5VFI{Pzl{NkO4
SUM190PT MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEO3OZY2OC9zMECvNlUxKG6P MVK0PEBp MnvYSG1UVw>? MnTpbY5lfWOnczDj[YxtKGSnYYToJIF1KDVyIH7NJJNmdnOrdHn2[Yx6 NU[xToYyOjN5OUK2N|g>
HCT1 Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XrNVAvOi9zLkCvOU4xKM7:TR?= NUmyfnV4OTJxMkSvN|YwPDhiaB?= MXXpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NEfTUYQzOzd5MECwNC=>
Lovo Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\1Z4JiOC5{L{GuNE82NjBizszN NGfaTG4yOi9{ND:zOk81QCCq M13vSYlv\HWlZYOgZ4VtdCCmZXH0bEBqdiClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MkjzNlM4PzByMEC=
AGS NWfyNmhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[wMlAyPS1zIN88US=> NVH6V4R1PzJiaB?= Mn3UbY5lfWOnczDj[YxtKGSnYYToJINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MWeyN|c1PTB{NB?=
Huh7 MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPFNoUyKM7:TR?= MlLKNlQhcA>? NV7Ueo1DTE2VTx?= M163UpJm\HWlZYOgZYJwfXRiMkClJJZq[WKrbHn0feKh NW[ybFRtOjN4NEO5N|M>
ECC1 MYnGeY5kfGmxbjDBd5NigQ>? NY\wRmwzPTByIH7N M1H3R|Uh\A>? MXrEUXNQ MnzObY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? MUiyN|U{ODd4OR?=
HEC1A M2\pcWZ2dmO2aX;uJGF{e2G7 MofUOVAxKG6P MVm1JIQ> M1rJeGROW09? NXjMXVFPcW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= NUj5OoRmOjN3M{C3Olk>
EN1 Mn;QSpVv[3Srb36gRZN{[Xl? NVvmUGtmPTByIH7N MkjLOUBl NFGz[3VFVVOR MVjpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NFnnSIczOzV|MEe2PS=>
MFE296 NV7qOYtlTnWwY4Tpc44hSXO|YYm= M2PJVlUxOCCwTR?= NG\EfVY2KGR? NYXpemltTE2VTx?= NGfPeG9qdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= NHvseGozOzV|MEe2PS=>
HASMCs NU\I[GRiTnWwY4Tpc44hSXO|YYm= M1fNR|AuPTByIH7N NEi0clM3KGR? MWLkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKQVTDJIFv\CClZXzsJJZq[WKrbHn0fS=> NFTEO5kzOzVzOES2Oy=>
U373 NXvaRpRTTnWwY4Tpc44hSXO|YYm= Ml3FNE4zPS9yLkWvNUDPxE1? M1nLNFI1KGh? MXvpcoNz\WG|ZYOgVHIuSiCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEXBfoFlSw>? MoPKNlM1PzRzN{G=
ARN8  NWXHRnQyTnWwY4Tpc44hSXO|YYm= M3\h[VAvODVvMjFOwG0> MV6yOEBp NHOwXodz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? NVjJUXpFOjN2N{C1OFA>
MCF7 MkS5SpVv[3Srb36gRZN{[Xl? M37LTlAvODVvMjFOwG0> M4\OT|I1KGh? NYfRTXJJemWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? NHvPc2UzOzR5MEW0NC=>
H1299  MVLGeY5kfGmxbjDBd5NigQ>? MnzyNE4{O+LCk{JCpOK2VQ>? M{fDclI1NzR6IHi= MUDEUXNQ NX;Z[5ZDcW6lcnXhd4V{KEVvY3HkbIVzcW5icILveIVqdiCuZY\lcJMh\G:|ZTDk[ZBmdmSnboTsfS=> NXjNb2duOjN2NkG5O|U>
H1299 NWH0bZlyTnWwY4Tpc44hSXO|YYm= MUGwMlUh|ryP M1rZNVQ5KGh? MWnEUXNQ NWTCSGNrcW6qaXLpeJMhfGinIH3p[5JifG:{eTDwc5RmdnSrYXygZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? MWmyN|Q3OTl5NR?=
H1299 MXXGeY5kfGmxbjDBd5NigQ>? M4rFbFAvPSEQvF2= NUi4Omc2PDhiaB?= MoHHSG1UVw>? MnzXbY5pcWKrdIOgeIhmKGmwdnHzbZZmdmW|c9MgJINwdWKrbnWge4l1cCC|aXzpZolvcW5? NGXNWHQzOzR4MUm3OS=>
MG-63  MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT5O4xEOC5|IN88US=> MY[xNk06PiCq MmPySG1UVw>? NV;TUpJHcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> MlXoNlM1PTF6MUe=
LM8 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PEVFAvOyEQvF2= M3HCd|EzNTl4IHi= M{fvOGROW09? NWHoeXI3cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> M1HmeVI{PDVzOEG3
K562 NGHEe5BHfW6ldHnvckBCe3OjeR?= NUjLS3NCOC53IN88US=> NXeycVM3OjRiaB?= MkTk[ZRp[W6xbB?= M4PBNoRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv M2nI[FI{PDNyOUW3
HEL NUH6S3hoTnWwY4Tpc44hSXO|YYm= NU\uZVlqOC53IN88US=> MUiyOEBp NGDjOJpmfGijbn;s M13PfoRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv NV\udm1IOjN2M{C5OVc>
HL60 NY\VepJTSXCxcITvd4l{KEG|c3H5 MVyxJO69VQ>? NUPKSmQ2OjRiaB?= M4jGNIlv\HWlZYRCpINmdGxiZHXheIg> NVTxbJhTOjN2MEC1NVk>
KG1 NWGwUlhGSXCxcITvd4l{KEG|c3H5 MYexJO69VQ>? NXXDNmprOjRiaB?= MWLpcoR2[2W|wrDj[YxtKGSnYYTo M1HmNlI{PDByNUG5
Kazumi Ml;YRZBweHSxc3nzJGF{e2G7 Mlr2NUDPxE1? NGO3c24zPCCq NX;FZ5VkcW6mdXPld:Kh[2WubDDk[YF1cA>? MlzlNlM1ODB3MUm=
K562 M3S0WWFxd3C2b4Ppd{BCe3OjeR?= MUSxJO69VQ>? M4\GTFI1KGh? NU\TV|Q6cW6mdXPld:Kh[2WubDDk[YF1cA>? M33tc|I{PDByNUG5
THP1 M2H6ZmFxd3C2b4Ppd{BCe3OjeR?= M3;JOlEh|ryP MnHaNlQhcA>? M4fld4lv\HWlZYRCpINmdGxiZHXheIg> NYHDXWF3OjN2MEC1NVk>
SH-SY5Y MnvHSpVv[3Srb36gRZN{[Xl? MkGxNlUxKG6P MnLGNVYhcA>? MmTjZ4hidmenczDlfJBz\XO|aX;uJJBifHSncn6gc4Yh\2WwZYOgbY53d2y4ZXSgbY4h[2ixbHXzeIVzd2xic4nueIhme2m|LDD1dJRic2ViYX7kJIVn\my3eB?= NGS0PVYzOzN{NkSyNi=>
HEK293 MUfGeY5kfGmxbjDBd5NigQ>? MnjNNUDDvU4EoB?= NUK1Z5RvOThiaNMg NVjiXIFZcW6qaXLpeJMhfGinIHvhcIlzcW5vNz3t[YRq[XSnZDDy[YNzfWm2bXXueEBw\iC|eX7wbIltcW5vMTDh[4dz\WejdHXzJIlvfG9iYXfndoV{d22ncx?= MUKyN|I5PDh2OB?=
HTK MYjGeY5kfGmxbjDBd5NigQ>? MkTlOFAxKG6P MonZO|IhcA>? MlLIbY5pcWKrdIOgWGdHNc7{4pETTY5lfWOnZDDNfY9ncWK{b3LsZZN1KESrZn\ldoVvfGmjdHnvci=> NWjDc|c2OjN{OESwNFI>
HTK MoizSpVv[3Srb36gRZN{[Xl? M3X4flExOC16MEDuUS=> NVLPUnAyPzJiaB?= M2jwb4Jtd2OtczDUS2Yu|rMkgKPJcoR2[2WmIGLPV{BidmRiSELPNuKhSWOldX31cIF1cW:w NUK3ZVIzOjN{OESwNFI>
Caco-2  MlzzSpVv[3Srb36gRZN{[Xl? M3rkZVEhyrWPwrC= M{fQS|I1KGh? MWjk[YNz\WG|ZYOgV2VTXCCycn;0[YlvKGW6cILld5Nqd25? MlS3NlMyQTVyN{C=
HeLa NW\PXWVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWCxNFAhdk1? M4PyWVI1KGh? NXXKRo5JTE2VTx?= MkTPTWM2OCCxZjCxNFBvVQ>? MWeyN|E3PTd2OB?=
HeLa NX7XbVhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;zOFAhdk1? Mn3DOFghcA>? NIHQXZlFVVOR NFPmZmpKSzVyIH;mJFQxdk1? NILFPGwzOzF4NUe0PC=>
HeLa M1K3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLzNlAhdk1? NFKybm04OiCq M2XnXGROW09? NVKxSlZDUUN3MDDv[kAzOG6P NXXWRXlXOjNzNkW3OFg>
HeLa MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4OwV|ExNzNyL{WwJI5O M1fae|czKGh? MWHEUXNQ MoPGbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiTV3QJEjPnM7qbTmgcI9{eyClZXzsd{Bld3OnIHTldIVv\GWwdHz5 NVPyc2lxOjNzNkW3OFg>
MDA-MB-231 M37rOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrENlUuPDByIH7N MYC0PEBp MnnXTWM2OCCxZjCyOlMvOm6PwrC= NIriNIwzOzB3NUG5PC=>
MCF-7  NI\HRlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D4UlI2NTRyMDDuUS=> M3rFXVQ5KGh? MXHJR|UxKG:oIEKyNE41dk1? MorHNlMxPTVzOUi=
ECC-1  NYf2RnB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDHNVAxKG6P NEfm[IgzPCCq M3\seYV1cGGwb3y= MlfnbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn M{XyTlI{ODJ6OECz
HEC-1A MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYCzTHFbOTByIH7N M4rRZ|I1KGh? NVvFeGdF\XSqYX7vcC=> NW\vb5d[cW6lcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGGyb4D0c5Rq[yCwdXPs[YkhfG9iM{ml M2TlXlI{ODJ6OECz
NHAC-kn M2HJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnwfZEyOC9zMECvOVAxKG6P NIflUmsyOiCq MX7EUXNQ NHHyeWlKSzVyIH;mJFUxOG6P NHrweHgzOzBzN{i3NS=>
A549 MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXiyOVAhdk1? NYLVd3poPi15MjDo NYP0W2loTE2VTx?= NUmx[XRR[2G3c3XzJIEh\3KnYYTldkBqdmirYnn0c5J6KGWoZnXjeEBkd22kaX7lJJdqfGhiVGjUJI9zKGW{bH;0bY5q[g>? M13jWFIzQTl2N{iw
MG-63 NY\sXoVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDNN|AxKG6P NX3Ce|FbOTJiaB?= M1nzc2ROW09? MW\pcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gPFYm MWWyNlc6QTN|OB?=
MG-63 M4[5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\5WVA2OzByIH7N NXX5cVY4OjRiaB?= M2\iTWROW09? Mn\LbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFY4LQ>? NIL5eZYzOjd7OUOzPC=>
MG-63 M3XyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnKS4hCOzByIH7N MX:0PEBp MUfEUXNQ M3TFXYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A2PiV? MYCyNlc6QTN|OB?=
HL60  NYraeWdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEW4eGIyPTBvM{WwJI5O MlT4NlQhcA>? M1OxeIlv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> NEfV[|YzOjd3M{ezPS=>
U937 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nhNlE2OC1|NUCgcm0> NH7nelIzPCCq NHPLV4NqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYRCpJdp\W5iY3;uZ4VvfHKjdHnvcpMhcGmpaHXyJJRp[W5iMkWwJI5O NXrteHBGOjJ5NUO3N|k>
SCC-6 NGja[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjJNlAxNTN{MECgcm0> NHHlTHcyOi9{ND:0PEBp Ml;OSG1UVw>? NY\jc5R6cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hd2ZiU1PDMVYh[2WubIOgbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy Mle3NlI2PTJ|MkG=
U87  M2DWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3X3XVExOC1|MECgcoc> NU\M[5cxOjRiaB?= MY\pcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gO|ImKCCjdDCyNFBv\w>? MX6yNlI4ODh2OR?=
K562 M1HtVmZ2dmO2aX;uJGF{e2G7 M{\sb|Eh|ryP MlHsNVIhcA>? MX\EUXNQ NYjjcYpF\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> NYrlSVBEOjJzN{mxPVg>
Reh MoLTSpVv[3Srb36gRZN{[Xl? M3jaNFAvOy9zIN88US=> NX7t[YdsOTJiaB?= MkLFSG1UVw>? NUGwfYQx\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> M3TpdlIzOTd7MUm4

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
EGFR / STAT3 ; 

PubMed: 31289542     


Expression of EGFR and STAT3 in PC3 cells treated with TSA. PC3 cells were plated in 6-cm dishes, and 0.25, 0.5 or 1 µM TSA was added for 24 h. DMSO was added into the control group wells. Cells were collected and lysed with lysis buffer and the protein expression analyzed via western blotting.

Cyclin D1 / CDK6 / CDK4 / p-RB / RB; 

PubMed: 31289542     


Expression of cyclin D1, CDK6, CDK4 and RB, and the phosphorylation of RB, was detected in PC3 cells treated with TSA for 24 h. 

MMP-1 / MMP-3 / MMP-13 / TIMP-1; 

PubMed: 27431944     


Chondrocytes were pretreated with increasing concentrations of TSA for 2 h, followed by stimulation with 5 ng/ml IL-1β for 24 h.

Acetyl-H3 (Lys27) / H3 (96C10) / Acetyl-H4(Lys8) / H4(L64C1); 

PubMed: 27431944     


Chondrocytes were treated with increasing concentrations of TSA for 24 h.

α-H3Ac / α-H4Ac / α-H3K9Ac / α-H3K9 S10 / α-H3K4 me / α-H3K4 me2 / α-H3K9 me2; 

PubMed: 23802098     


Histone acetylation occurs directly at the promoter region of IL-23R. The ChIP assay demonstrates that TSA treatment results in an increase in the acetylation of histone H3 and H4. A549 cells were cultured in the presence or absence of TSA (250 ng/mL) for a period of 24 h. Subsequently, a ChIP assay was performed using the following antibodies; pan acetyl-histone H3 (H3Ac), pan acetyl-histone H4 (H4Ac), acetyl-histone H3 Lys 9 (H3K9Ac), acetyl-histone H3 Lys 9/14 (H3K9/14ac), acetyl-histone H3 Lys 9 phosphoSer10 (H3K9S10), methyl-histone H3 Lys 4 (H3K4Me), di methyl-histone H3 Lys 4 (H3K4Me2), and di methyl-histone H3 Lys 9 (H3K9Me2). Input DNA serves as a positive control as recommended by the manufacturer (Diagenode). A no antibody control was included to test for non-specific binding (UT, untreated; TSA, Trichostatin A).

31289542 27431944 23802098
Immunofluorescence
α-C/EBPβ / α-HP1α ; 

PubMed: 21122806     


3T3-L1 preadipocytes were grown on coverslips for three days and induced to differentiate by treatment with MDI (48 h) in the presence of vehicle (-TSA) or 87 nM Trichostatin A (+TSA). Under these experimental conditions: A-H Cells were fixed and permeabilized in cold methanol, subjected to IIF with the indicated antibodies, and nuclei were counterstained with DAPI. Scale bar, 5 μm. 

α-HDAC1 ; 

PubMed: 29045501     


MCF-7 cells were treated with indicated concentrations of trichostatin A (optical sections E-H, respectively) for 12 hours, fixed, permeabilized and optical sections were obtained by laser scanning confocal microscopy. Fluorescence signal for HDAC1 is shown in green (left panels), DAPI staining is shown in blue (middle panels), and merged optical sections are shown in the right panels.

α-tubulin / acetylated histone 3; 

PubMed: 27957719     


Immunocytochemistry for acetylated α-tubulin (red) and acetylated histone 3 (green) on N2a cells treated with 1 μM TSA, ACY-738, and ACY-775.

21122806 29045501 27957719
Growth inhibition assay
Cell viability (A549 cells); 

PubMed: 27571418     


Cytotoxicity of histamine determined by MTT assay in A549 cells.

Cell viability (MDA-MB-231 cells); 

PubMed: 27548148     


The human breast cancer cells (MDA-MB-231) were incubated with various concentrations of TSA (0–300 nM) for 24 h. Cell viability was measured by WST-8.

Cell viability (PC3 cells); 

PubMed: 31289542     


PC3 cells were plated in a 96-well plate and treated with different doses of TSA (0, 0.25, 0.5 and 1 µM) for 72 h; an MTT assay was used to measure the effects of TSA on PC3 cell proliferation.

27571418 27548148 31289542
In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

- Collapse

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

- Collapse
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A
Smiles CC(C=C(C)C=CC(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04606771 Recruiting Drug: Osimertinib + Savolitinib|Drug: Savolitinib + Placebo Non-Small Cell Lung Cancer AstraZeneca September 28 2020 Phase 2
NCT03901053 Recruiting Device: Reaktiv AFO|Device: PhatBrace AFO Foot Injuries and Disorders Jason Wilken|Minneapolis Veterans Affairs Medical Center|Walter Reed National Military Medical Center|Henry M. Jackson Foundation for the Advancement of Military Medicine|Center for Veterans Research and Education|University of Delaware|Johns Hopkins Bloomberg School of Public Health|University of Iowa February 27 2020 Not Applicable
NCT03887650 Recruiting Drug: Liposomal Bupivicaine 1.3%|Drug: Bupivacaine 0.5% Post-operative Pain|Total Shoulder Arthroplasty|Osteoarthritis of the Shoulder|Pain Management Hartford Hospital January 14 2019 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID